Moleculin Biotech, Inc.MBRXEarnings & Financial Report
Moleculin Biotech, Inc. is a clinical-stage biotechnology company focused on developing innovative oncology therapies for difficult-to-treat cancers. Its core pipeline includes candidates targeting brain tumors, pancreatic cancer and other rare malignancies, with primary operations in the United States addressing high unmet patient needs.
MBRX Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-7.5M
Net Profit
$15.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-25.96
Moleculin Biotech, Inc. Q4 FY2025 Financial Summary
Moleculin Biotech, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of $15.6M (up 336.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $15.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Moleculin Biotech, Inc. Annual Revenue by Year
Moleculin Biotech, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
Moleculin Biotech, Inc. Quarterly Revenue & Net Profit History
Moleculin Biotech, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $15.6M | N/A |
| Q3 FY2025 | $0 | — | $-25.4M | N/A |
| Q2 FY2025 | $0 | — | $-17.8M | N/A |
| Q1 FY2025 | $0 | — | $-5.9M | N/A |
| Q4 FY2024 | $0 | — | $-6.6M | N/A |
| Q3 FY2024 | $0 | — | $-7.0M | N/A |
| Q2 FY2024 | $0 | — | $-6.0M | N/A |
| Q1 FY2024 | $0 | — | $-6.4M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $30.8M | $25.6M | $23.4M | $16.9M | $21.0M | $21.6M | $20.4M | $22.1M |
| Liabilities | $9.3M | $7.9M | $15.9M | $5.7M | $7.2M | $25.2M | $47.3M | $7.1M |
| Equity | $25.0M | $19.4M | $17.4M | $11.2M | $13.8M | $-3.6M | $-26.9M | $15.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.7M | $-5.9M | $-6.1M | $-5.1M | $-4.6M | $-5.6M | $-7.2M | $-5.4M |